Psychiatry

FDA grants Fast Track to NRX-100, the first preservative-free IV ketamine, for treating suicidal ideation in depression.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

Kratom poses serious addiction risks despite its natural appeal, misleading many into believing it's a safe alternative for pain and withdrawal relief.

This July psychiatry month in review features FDA news, depression trials, links between healthy habits and mental health, and SoCal Psych 2025 highlights.

A new study found patients with HS are significantly more likely to develop new-onset depression and anxiety, regardless of disease severity.

Findings suggest 7000 steps per day is associated with a reduced risk of health outcomes including mortality, cardiovascular disease, and type 2 diabetes.

Phase 4 trial shows esketamine provides significant symptom relief in patients with treatment-resistant depression within 24 hours of the first dose.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

In this Q&A, Alva discusses how to identify tardive dyskinesia, approaches for treatment-resistant depression, and emerging therapies.

At 2025 So Cal Psych, Maguire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

Patients who adhered to a strict 12-week low FODMAP diet saw improvements in fatigue, anxiety, and depression, and performed better on an attention test.

At So Cal Psych 2025, Monroe discusses the promise of xanomeline-trospium (Cobenfy) and its novel mechanism.

Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

Stay updated with the latest healthcare breakthroughs, including FDA news, clinical trial data, and regulatory submissions, in this week's essential news roundup.

Discover cutting-edge insights on schizophrenia, mood disorders, and digital therapeutics at the 2025 Southern California Psychiatry Conference.

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

Explore the transformative potential of MDMA-assisted therapy and psychedelics in treating PTSD and addiction, offering hope where traditional methods fail.

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

Discover how structured routines and exercise enhance mental health for those with bipolar disorder, fostering stability, and community support.

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.

5 FDA updates in psychiatry from the first half of 2025, plus other pipeline developments in psychiatry for depression, schizophrenia, and OUD.

This Q2 psychiatry recaps promising data of COMP360 for treatment-resistant depression, the expansion of clozapine access, and experts weighing in on new data and ethical debates.